Navigation Links
Drug could improve working memory of people with autism, study finds
Date:4/15/2013

COLUMBIA, Mo. People with an Autism Spectrum Disorder (ASD) often have trouble communicating and interacting with others because they process language, facial expressions and social cues differently. Previously, researchers found that propranolol, a drug commonly used to treat high blood pressure, anxiety and panic, could improve the language abilities and social functioning of people with an ASD. Now, University of Missouri investigators say the prescription drug also could help improve the working memory abilities of individuals with autism.

Working memory represents individuals' ability to hold and manipulate a small amount of information for a short period; it allows people to remember directions, complete puzzles and follow conversations. Neurologist David Beversdorf and research neuropsychologist Shawn Christ found that propranolol improves the working memory performance of people with an ASD.

"Seeing a tiger might signal a fight or flight response. Nowadays, a stressor such as taking an exam could generate the same response, which is not helpful," said Beversdorf, an associate professor in the Departments of Radiology and Neurology in the MU School of Medicine. "Propranolol works by calming those nervous responses, which is why some people benefit from taking the drug to reduce anxiety."

Propranolol increased working memory performance in a sample of 14 young adult patients of the MU Thompson Center for Autism and Neurodevelopmental Disorders but had little to no effect on a group of 13 study participants who do not have autism. The researchers do not recommend that doctors prescribe propranolol solely to improve working memory in individuals with an ASD, but patients who already take the prescription drug might benefit.

"People with an Autism Spectrum Disorder who are already being prescribed propranolol for a different reason, such as anxiety, might also see an improvement in working memory," said Christ, an associate professor in the Department of Psychological Sciences in the MU College of Arts and Science.

Future research will incorporate clinical trials to assess further the relationship between cognitive and behavioral functioning and connectivity among various regions of the brain.

The study, "Noradrenergic Moderation of Working Memory Impairments in Adults with Autism Spectrum Disorder," was published in the Journal of the International Neuropsychological Society. Kimberly Bodner, a psychological sciences doctoral student at MU, and Sanjida Saklayen from the Ohio State University College of Medicine co-authored the study.

Beversdorf also has an appointment in the MU Department of Psychological Sciences. Beversdorf and Christ conduct research at the Thompson Center. As the largest center in Missouri specializing in ASD and other developmental disorders, the Thompson Center is a national leader in confronting the challenges of autism and other developmental conditions through its collaborative programs that integrate research, clinical service delivery, education and public policy.


'/>"/>

Contact: Jesslyn Chew
ChewJ@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. La Jolla Institutes surprising finding could alter the face of dengue vaccine development
2. Changes to Psychiatrys Bible Could Widen Definition of ADHD
3. Gulp! Study Suggests Super-Size Soda Ban Could Fizzle
4. Transparent Mouse Brain Could Shed Light on Human Brain Health
5. Could Coffee Bean Extract Help Control Blood Sugar?
6. Penn study finds increased sleep could reduce rate of adolescent obesity
7. New Study Results May Suggest That Appetite Suppressants Like Prescopodene Could Help Pull You Out of a Bad Mood
8. Electrical Stimulation Could Zap the Need for Physical Therapy Following Knee Replacement
9. College Sports Could Raise Players Risk for Depression, Study Finds
10. Could Scientists Peek Into Your Dreams?
11. Balding Men Could Face Higher Heart Risks, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: